JP4819356B2 - 細胞及び作用物質を担持する微小粒子 - Google Patents
細胞及び作用物質を担持する微小粒子 Download PDFInfo
- Publication number
- JP4819356B2 JP4819356B2 JP2004500842A JP2004500842A JP4819356B2 JP 4819356 B2 JP4819356 B2 JP 4819356B2 JP 2004500842 A JP2004500842 A JP 2004500842A JP 2004500842 A JP2004500842 A JP 2004500842A JP 4819356 B2 JP4819356 B2 JP 4819356B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- microparticles
- microparticle
- poly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/622—Microcapsules
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Botany (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
−それらは、細胞(又はその断片)の培養用担体として役立ち得る。移植する細胞の微小粒子に対する好ましい付着により、それらを採集するために、明白な、衛生上の安全の理由で勧められない動物由来のタンパク質分解酵素を使用せずに、それらの調製、更にはそれらの試験管内形質転換が可能になる。
−それらは、移植細胞(又は細胞分画)への担体として役立ち、かつ埋め込み後に毒性なしに分解し得、移植細胞(又はその断片)の組み込みに干渉しない。
−それらは、プログラムされた期間に、かつ一定の分量で1つ又は幾つかの成長因子又はサイトカインを放出し得る。
−それらは、移植細胞の生存率及び分化を促進し、その微小環境、並びに宿主組織中へのそれらの組み込みを変更し得る。
−(血液幹細胞から生じた樹状細胞による予防接種の範囲で)試験管内で樹状細胞と接触させられるためであるか、
−皮下、真皮内、又は筋肉内から患者の直接投与されるためである。
回収された膜タンパク質の量を決定するために、ローリーテストを実施する分量決定が、行われた。(0.2〜1μg/μLの)BSAの基準範囲を使用して、試料のタンパク質濃度を計算することができた。精製開始時に(溶解の直後に)採取され、かつ細胞のタンパク質の集合を含む、初期アリコート(Ai)と呼ばれるアリコートは、7000〜10000μg/μLのタンパク質濃度を示した。それに反して、濃縮終了時には、200〜300μg/μLのタンパク質濃度が得られる。従って我々は、タンパク質全体の3%を回収した。
共焦点顕微鏡の膜マーカー(5’−ヌクレオチダーゼ、インテグリン、ICAM−1)の直接免疫蛍光法は、微小粒子に対する膜タンパク質の固定を確認する。
Claims (11)
- 生体適合性かつ生分解性材料を主成分とする微小粒子であって、
前記材料は、移植細胞を表面に有し、前記細胞は、成人自己細胞、胚性細胞、幹細胞、肝細胞、ランゲルハンス島、神経細胞、筋細胞、造血細胞および骨細胞からなる群から選択され、
前記微小粒子は、該微小粒子中に取り込まれ、埋め込みの際に前記細胞又はその環境に対して活性である少なくとも1つの作用物質を含み、前記微小粒子は、10〜500μmの直径を有し、そして、前記生体適合性かつ生分解性材料に細胞の付着を可能にする、細胞に対して活性であるか、不活性である細胞接着性化合物のコーティングをさらに含み、前記細胞接着性化合物は、RGD配列を含む化合物、ポリ−D−リジン、ポリ−L−リジン、ポリオルニチン、ポリエチレンアミンおよびフィブロネクチン類からなる群より選択され、
前記作用物質は、成長因子、ホルモンおよびサイトカインからなる群より選択され、前記微小粒子によって、持続して、かつ制御されて放出されることを特徴とする微小粒子。 - 生体適合性かつ生分解性材料は、ポリマー又はコポリマーであることを特徴とする請求項1に記載の微小粒子。
- ポリマー又はコポリマーは、ポリエステル、ポリホスファゼン及びそれらの混合物からなる群から選択されることを特徴とする請求項2に記載の微小粒子。
- ポリエステルは、ポリε−カプロラクトン、ポリ(オルトエステル)又はポリ(α−ヒドロキシ酸)であることを特徴とする請求項3に記載の微小粒子。
- ポリ(α−ヒドロキシ酸)は、ポリラクチド又はPLGAであることを特徴とする請求項4に記載の微小粒子。
- 細胞は、腫瘍の初代培養から得られる自己腫瘍細胞であることを特徴とする請求項1から5のいずれかに記載の微小粒子。
- 少なくとも1つの作用物質は、GM−CSF、IL12、IL4又はIL18から選択される炎症誘発性サイトカイン或いはフロイントアジュバントであることを特徴とする請求項1〜6のいずれかに記載の微小粒子。
- 組織修復のための医薬品組成物を調製するための、請求項1〜7のいずれかに記載の微小粒子の使用。
- 遺伝子導入のための医薬品組成物を調製するための、請求項1〜7のいずれかに記載の微小粒子の使用。
- ワクチンのための医薬品組成物を調製するための、請求項1〜7のいずれかに記載の微小粒子の使用。
- 抗腫瘍医薬品組成物を調製するための、請求項1〜7のいずれかに記載の微小粒子の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0205574A FR2839260B1 (fr) | 2002-05-03 | 2002-05-03 | Microparticules a base d'un materiau bicompatible et biodegradable, supportant des cellules et des substances biologiquement actives |
FR02/05574 | 2002-05-03 | ||
PCT/FR2003/001377 WO2003092657A1 (fr) | 2002-05-03 | 2003-05-02 | Microparticules supportant des cellules et des substances actives |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011040940A Division JP2011153143A (ja) | 2002-05-03 | 2011-02-25 | 細胞及び作用物質を担持する微小粒子 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005525407A JP2005525407A (ja) | 2005-08-25 |
JP4819356B2 true JP4819356B2 (ja) | 2011-11-24 |
Family
ID=29226179
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004500842A Expired - Lifetime JP4819356B2 (ja) | 2002-05-03 | 2003-05-02 | 細胞及び作用物質を担持する微小粒子 |
JP2011040940A Pending JP2011153143A (ja) | 2002-05-03 | 2011-02-25 | 細胞及び作用物質を担持する微小粒子 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011040940A Pending JP2011153143A (ja) | 2002-05-03 | 2011-02-25 | 細胞及び作用物質を担持する微小粒子 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1507517B1 (ja) |
JP (2) | JP4819356B2 (ja) |
AU (1) | AU2003249390A1 (ja) |
CA (1) | CA2483707C (ja) |
ES (1) | ES2626204T3 (ja) |
FR (1) | FR2839260B1 (ja) |
WO (1) | WO2003092657A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10980858B2 (en) | 2016-06-20 | 2021-04-20 | Fujifilm Corporation | Trophic factor releasing agent and inflammatory disease treating agent |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050214377A1 (en) * | 2004-03-24 | 2005-09-29 | Sanjay Mistry | Microparticles for cell delivery |
ES2877206T3 (es) * | 2008-09-18 | 2021-11-16 | Evonik Corp | Proceso de microencapsulación con disolvente y sal |
CN102597230A (zh) * | 2009-11-13 | 2012-07-18 | 株式会社日立高新技术 | 含有粒子的细胞聚集体 |
CA2873404C (en) * | 2011-06-02 | 2022-08-30 | The Regents Of The University Of California | Membrane encapsulated nanoparticles and method of use |
WO2013144341A1 (en) | 2012-03-30 | 2013-10-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Microsphere compositions, preparation method and applications thereof |
WO2015021390A2 (en) | 2013-08-08 | 2015-02-12 | The Regents Of The University Of California | Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis |
CN106163504B (zh) | 2014-03-20 | 2021-02-09 | 加利福尼亚大学董事会 | 水凝胶毒素-吸收或结合纳米颗粒 |
CN107530285B (zh) | 2015-04-29 | 2021-07-27 | 加利福尼亚大学董事会 | 使用纳米粒子解毒 |
CN111346236B (zh) * | 2018-12-21 | 2023-03-14 | 中国医学科学院生物医学工程研究所 | 负载肿瘤抗原的聚多巴胺纳米粒子及其制备方法与应用 |
JPWO2020203965A1 (ja) * | 2019-03-30 | 2020-10-08 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11193246A (ja) * | 1997-05-19 | 1999-07-21 | Sumitomo Pharmaceut Co Ltd | 免疫増強製剤 |
JP2001010961A (ja) * | 1999-02-09 | 2001-01-16 | Inst Of Physical & Chemical Res | 腫瘍ワクチン |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2470794A1 (fr) * | 1979-12-05 | 1981-06-12 | Pasteur Institut | Nouvelles microparticules, leur preparation et leurs applications en biologie, notamment a la culture de cellules diploides humaines |
US6309669B1 (en) * | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
US4975526A (en) * | 1989-02-23 | 1990-12-04 | Creative Biomolecules, Inc. | Bone collagen matrix for zenogenic implants |
JPH04360682A (ja) * | 1991-06-06 | 1992-12-14 | Kurabo Ind Ltd | 細胞培養用担体 |
JPH0581A (ja) * | 1991-06-21 | 1993-01-08 | Koken Co Ltd | 細胞培養担体及び培養方法 |
GB9210574D0 (en) * | 1992-05-18 | 1992-07-01 | Ca Nat Research Council | Biotherapeutic cell-coated microspheres for wound/burn and prothesis implant applications |
US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
JPH09255777A (ja) * | 1996-03-21 | 1997-09-30 | Japan Synthetic Rubber Co Ltd | 担 体 |
US6042820A (en) * | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
UA54505C2 (uk) * | 1997-04-03 | 2003-03-17 | Гілфорд Фармасьютікалз Інк. | Полімери, що біологічно розкладаються, зшиті фосфатами, композиції, вироби і способи для їх виготовлення і використання |
ATE354600T1 (de) * | 1997-05-12 | 2007-03-15 | Metabolix Inc | Polyhydroxyalkanoate für in vivo anwendungen |
EP2283880A3 (en) * | 2000-03-20 | 2014-07-09 | Biosphere Medical, Inc. | Injectable microspheres for tissue construction |
-
2002
- 2002-05-03 FR FR0205574A patent/FR2839260B1/fr not_active Expired - Lifetime
-
2003
- 2003-05-02 JP JP2004500842A patent/JP4819356B2/ja not_active Expired - Lifetime
- 2003-05-02 CA CA2483707A patent/CA2483707C/fr not_active Expired - Lifetime
- 2003-05-02 AU AU2003249390A patent/AU2003249390A1/en not_active Abandoned
- 2003-05-02 ES ES03747486.3T patent/ES2626204T3/es not_active Expired - Lifetime
- 2003-05-02 WO PCT/FR2003/001377 patent/WO2003092657A1/fr active Application Filing
- 2003-05-02 EP EP03747486.3A patent/EP1507517B1/fr not_active Expired - Lifetime
-
2011
- 2011-02-25 JP JP2011040940A patent/JP2011153143A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11193246A (ja) * | 1997-05-19 | 1999-07-21 | Sumitomo Pharmaceut Co Ltd | 免疫増強製剤 |
JP2001010961A (ja) * | 1999-02-09 | 2001-01-16 | Inst Of Physical & Chemical Res | 腫瘍ワクチン |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10980858B2 (en) | 2016-06-20 | 2021-04-20 | Fujifilm Corporation | Trophic factor releasing agent and inflammatory disease treating agent |
Also Published As
Publication number | Publication date |
---|---|
WO2003092657A1 (fr) | 2003-11-13 |
ES2626204T3 (es) | 2017-07-24 |
FR2839260B1 (fr) | 2005-02-25 |
EP1507517A1 (fr) | 2005-02-23 |
JP2011153143A (ja) | 2011-08-11 |
CA2483707A1 (fr) | 2003-11-13 |
JP2005525407A (ja) | 2005-08-25 |
CA2483707C (fr) | 2012-03-06 |
EP1507517B1 (fr) | 2017-03-08 |
FR2839260A1 (fr) | 2003-11-07 |
AU2003249390A1 (en) | 2003-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011153143A (ja) | 細胞及び作用物質を担持する微小粒子 | |
US9579287B2 (en) | Microparticles supporting cells and active substances | |
US11890303B2 (en) | Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse | |
Orive et al. | Biocompatibility of microcapsules for cell immobilization elaborated with different type of alginates | |
Yu et al. | The use of human mesenchymal stem cells encapsulated in RGD modified alginate microspheres in the repair of myocardial infarction in the rat | |
Wang et al. | Therapeutic cell delivery and fate control in hydrogels and hydrogel hybrids | |
Murua et al. | Cell microencapsulation technology: towards clinical application | |
US8197553B2 (en) | Composite scaffolds and methods using same for generating complex tissue grafts | |
Tatard et al. | Pharmacologically active microcarriers: a tool for cell therapy | |
CN104470505B (zh) | 微球组合物及其制备方法和应用 | |
Leung et al. | Tissue transplantation by stealth—coherent alginate microcapsules for immunoisolation | |
Garate et al. | Assessment of the behavior of mesenchymal stem cells immobilized in biomimetic alginate microcapsules | |
Shanbhag et al. | Neural progenitor cells grown on hydrogel surfaces respond to the product of the transgene of encapsulated genetically engineered fibroblasts | |
Zilberman et al. | Polymer‐encapsulated engineered adult mesenchymal stem cells secrete exogenously regulated rhBMP‐2, and induce osteogenic and angiogenic tissue formation | |
Kim et al. | Biomaterials for stem cell therapy for cardiac disease | |
Sapin et al. | Development of new polymer-based particulate systems for anti-glioma vaccination | |
Mendez et al. | Sustained intracerebral delivery of nerve growth factor with biodegradable polymer microspheres | |
Orive et al. | Recent advances in the use of encapsulated cells for effective delivery of therapeutics | |
Filipovic-Gric et al. | Microparticles with neuroactive agents | |
Tai | The microencapsulation of cells: immunological isolation and the application in somatic gene therapy. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060424 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100122 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100331 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100407 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100524 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101029 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110225 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110425 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110510 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110628 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110714 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110805 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110901 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140909 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4819356 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |